Quality of life in glioblastoma after the introduction of temozolomide: a systematic review
DOI:
https://doi.org/10.33448/rsd-v11i15.37205Keywords:
Quality of Life; Glioblastoma; Temozolomide.Abstract
Introduction: Gliomas are primary tumors of the central nervous system with an aggressive pattern of progression with a poor prognosis in terms of survival and quality of life. The current standard treatment consists of surgery with maximum excision associated with radiotherapy and chemotherapy, based mostly on the use of temozolomide. Since its introduction, the quality of life of patients undergoing this therapy has not been widely targeted and evaluated. Objective: To verify the quality of life of patients with glioblastoma after the introduction of temozolomide in the therapeutic protocols. Methods: A systematic literature review guided by the PICO and PRISMA protocol was conducted; PubMed, Medline and Lilacs databases were consulted. Results: Initially, 77 studies were found, after selection criteria, 35 articles were analyzed. No statistically significant change was found in overall quality of life in studies that analyzed temozolomide therapy versus different control therapies. Conclusion: The association of temozolomide with surgery and radiotherapy proved to be neutral, with no significant negative or positive impacts on the quality of life of patients with glioblastoma.
References
Arakawa, Y. et al. (2021). A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 ( AgedGlio -PIII), BMC Cancer, 21 (1), 1-8.
Armstrong, T. S. et al. (2013). Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma, Journal of Clinical Oncology, 31 (32), 4076-4084.
Baba, M. A., Adali, N. (2021). Neurocognitive state and quality of life of patients with glioblastoma in Mediterranean countries: a systematic review. Annals of Palliative Medicine, 10 (11), 11980-11993.
Badruddoja, M. A. et al. (2017). Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma, Cancer Chemotherapy and Pharmacology, 80 (4), 715-721.
Brada, M. et al. (2001). Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse, Annals of Oncology, 12 (2), 259-266.
Brada, M. et al. (2005). Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide, Annals of Oncology, 16 (6), 942-949.
Braun, K. & Ahluwalia, M. S. (2017). Treatment of glioblastoma in older adults, Current Oncology Reports, 19 (12), 1-7.
Campos, J. A. D. B. et al. (2018). European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30: models factorials in patients Brazilians with cancer, Einstein (Sao Paulo), 16 (1), 1-8.
Caroli, M. et al. (2007). Temozolomide in glioblastoma: results of administration first relapse and in newly diagnosed cases. Is an alternative schedule to concomitant protocol still proposed?, Journal of Neuro-oncology, 84 (1), 71-77.
Chibbaro, S. et al. (2004). Temozolomide as a first-line agent in treating high-grade gliomas: phase II study, Journal of Neuro-oncology, 67 (1), 77-81.
Chiu, Leonard et al. (2012). Quality of life in patients with primary and metastatic brain cancer as reported in the literature using the EORTC QLQ-BN20 and QLQ-C30, Expert Review of Pharmacoeconomics & Outcomes Research, 12 (6), 831-837.
Davis, M. E. & Mulligan Stoiber, A. M. (2011). Glioblastoma multiforme : enhancing survival and quality of life, Clinical Journal of Oncology Nursing, 15 (3), 291-297.
Dinnes, J., Cave, C., Huang, S. & Milne, R. (2002). A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma, British Journal of Cancer, 86 (4), 501-505.
Domenech, M., Hernandez, A. & Balana, C. (2021). The need for geriatric scales in glioblastoma. Aging (Albany NY), 13 (14), 17959-17960.
Hamilton, D. A. (2006). Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma. Cancer Treatment Reviews, 32 (6), 483-486.
Hanna, C. et al.(2020). Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis, Cochrane Database of Systematic Reviews, 3 (3), 1-133.
Karachi, A., Dastmalchi, F., Mitchel, D. A. & Rahman, M. (2018). Temozolomide for immunomodulation in the treatment of glioblastoma, Neuro-Oncology, 20 (12), 1566-1572.
Khan , R. B. et al. (2002). A phase II study of extended low-dose temozolomide in recurrent malignant gliomas, Neuro-oncology, 4 (1), 39-43.
Kocher, M. et al. (2008). Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma, Strahlentherapie und Onkologie, 184 (11), 572-579.
Kong, D. S. et al. (2010). Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma, Neuro-oncology, 12 (3), 289-296.
Lim, M., Xia, Y., Bettegowda, C. & Weller, M. (2018). Current state of immunotherapy for glioblastoma, Nature Reviews Clinical Oncology, 15 (7), 422-442.
Lombardi, G. et al. (2018). Quality of life perception, cognitive function, and psychological status in a real-world population of glioblastoma patients treated with radiotherapy and temozolomide, American Journal of Clinical Oncology, 41 (12), 1263-1271.
Lukas, R. V., Razis, E. D., Huse, J. T. (2021). An international perspective on the management of glioblastoma, Chinese Clinical Oncology, 10 (4), 107.
Malmstrom, A. et al. (2012). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized , phase 3 trial, The Lancet Oncology, 13 (9), 916-926.
McBain, C. et al. (2021). Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis, Cochrane Database of Systematic Reviews, 5 (1), 1-135.
Minniti, G. et al. (2009). Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma, Journal of Neuro-oncology, 91 (1), 95-100.
Minniti, G. et al. (2013). Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide, International Journal of Radiation Oncology, Biology, Physics, 86 (2), 285-291.
Mir, T., Pond, G. & Greenspoon, J. N. (2021). Outcomes in elderly patients with glioblastoma multiforme treated with short-course radiation alone compared to short-course radiation and concurrent and adjuvant temozolomide based on performance status and extent of resection, Current Oncology, 28 (4), 2399-2408.
Osoba, D., Brada, M, Yung, W. K. & Prado, M. (2000). Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme, Journal of Clinical Oncology, 18 (7), 1481-1491.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D. et al. (2021). The PRISMA 2020 statement : an updated guideline for reporting systematically reviews, BMJ, 372 (71), 1-9.
Paulsen, F. et al. (1999). Chemotherapy in the treatment of recurrent glioblastoma multiforme : ifosfamide versus temozolomide . Journal of Cancer Research and Clinical Oncology, 125 (7), 411-418.
Pedretti, S. et al. (2019). Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial, Journal of Neuro-Oncology, 143 (3), 447-455.
Perry, J. R. et al. (2017). Short-course radiation plus temozolomide in elderly patients with glioblastoma, New England Journal of Medicine, 376 (11), 1027-1037.
Pessini, L. (2009). Distanásia: até quando investir sem agredir?, Revista Bioética, 4 (1), 1-11.
Reddy, K. et al. (2013). Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide, Journal of Neuro-oncology, 114 (1), 111-116.
Reyes-Botero, G. et al. (2018). Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial (ATAG), The Oncologist, 23 (5), 524-e44.
Santos, C. M. C., Pimenta, C. A. M., Nobre, M. R. C. (2007). A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Revista Latino-Americana de Enfermagem, 15 (1), 508-511.
Schafer, N. et al. (2018). Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT- nonmethylated glioblastoma, Neuro-oncology, 20 (7), 975-985.
Sim, H. W., Nowak, A. K., Lwin, Z. & Khasraw, M. (2021). Management of glioblastoma: an Australian perspective, Chinese Clinical Oncology, 10 (4), 42.
Stahl, P. et al. Health-related quality of life and emotional well-being in patients with glioblastoma and their relatives, Journal of Neuro-Oncology, 149 (2), 347-356.
Taphoorn, M. J. B. et al. (2005). Health- related quality of life in patients with glioblastoma: a randomized controlled trial, The Lancet Oncology, 6 (12), 937-944.
Taphoorn, M. J. B. et al. (2015). Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide , and radiotherapy in newly diagnosed glioblastoma, Journal of Clinical Oncology, 33 (9), 2166-2175.
Taphoorn, M. J. B. et al. (2018). Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial, JAMA Oncology, 4 (4), 495-504.
Weller, J. et al. (2019). Health-related quality of life and neurocognitive functioning with lomustine – temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma ( CeTeG /NOA-09): A randomized , multicentre , open-label, phase 3 trial, The Lancet Oncology, 20 (10), 1444-1453.
Wirsching, H.G., Galanis, E. & Weller, M. (2016). Glioblastoma, Hand Clin Neuro, 134 (1), 381-397.
YIin, A. et al. (2013). Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis, Plos One, 8 (9), e74242.
Yin, A. et al. (2014). A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients, Journal of Neuro-oncology, 116 (2), 315-324.
Yung, W. K. A et al. (200). A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, British Journal of Cancer, 83 (5), 588-593.
Zhu, J. J. et al. (2017). Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma, Journal of Neuro-oncology, 135 (3), 545-552.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Thales Augusto Oliveira Dias; Dyecika Souza Couto; Edvaldo José Rodrigues Cardoso
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
